Stay updated on ARGX-113 in ITP Patients Clinical Trial
Sign up to get notified when there's something new on the ARGX-113 in ITP Patients Clinical Trial page.

Latest updates to the ARGX-113 in ITP Patients Clinical Trial page
- Check7 days agoChange DetectedThe ARGX-113 Phase 2 study record for primary immune thrombocytopenia is now displayed, with details on its design, participant criteria, study locations, and outcome measures. The record indicates that the study is completed and no longer recruiting.SummaryDifference55%

- Check14 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0. The study record remains inaccessible behind a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoChange DetectedA banner announces an NIH-wide transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check27 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.1 to v3.7.2, while the page continues to display a 403 error.SummaryDifference0.2%

- Check34 days agoChange DetectedThe site footer’s revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now displays a 403 Forbidden error page, replacing the study content with a simple header and a Home button. This indicates the record is currently inaccessible.SummaryDifference17%

Stay in the know with updates to ARGX-113 in ITP Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARGX-113 in ITP Patients Clinical Trial page.